PROGNOSTIC BIOMARKER OF INVASIVE BREAST CANCER ANALYSIS AND MOLECULAR INTERACTION WITH Taxus sumatrana PHYTOCOMPOUNDS

Muhammad Faisal; Riyanda Indrawan Sani

doi:10.36526/biosense.v9i3.8018

Authors

Muhammad Faisal Department of Pharmacology, Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Sumatera Utara, Medan 20217 Indonesia
Riyanda Indrawan Sani Department of Pharmacology, Faculty of Medicine and Health Sciences, Universitas Muhammadiyah Sumatera Utara, Medan 20217 Indonesia

DOI:

https://doi.org/10.36526/biosense.v9i3.8018

Keywords:

Biomarker, Invasive breast cancer, Phytocompounds, Taxus sumatrana

Abstract

Invasive breast cancer remains a leading cause of cancer mortality, requiring reliable prognostic biomarkers and new therapeutic agents. Taxus sumatrana contains bioactive compounds with potential anticancer activity. We aimed to analyze gene expression data and identify the worst prognostic of invasive breast cancer as well as analyzing molecular interaction with compounds of T. sumatrana. Gene expression analysis data was conducted by mining transcriptomic and Kaplan-Meier data from the UALCAN database to compare breast tumor and normal tissues and evaluated survival among 100 candidate genes. PGK1 was selected based on high expression and poor prognosis. Subsequently, 31 compounds of T. sumatrana from the KNApSAcK database were subjected to molecular docking against PGK1. PGK1 demonstrated significantly stronger expression in primary tumor tissues than normal tissues. This expression was associated with the poorest survival trend among analyzed biomarkers (TAGLN2, TUBA1B, and COX7B), indicating its prognostic relevance. Taxinine B, Tasumatrol X, and Tasumatrol U were identified as promising compounds according to their favorable binding affinities toward the active site of PGK1, forming hydrogen bonds and hydrophobic interactions at key residues. PGK1 is a promising poor prognostic biomarker and therapeutic target in invasive breast cancer. Taxinine B from T. sumatrana may act as potential PGK1 inhibitors and merit further experimental validation.

References

Afendi, F. M., Okada, T., Yamazaki, M., Hirai-Morita, A., Nakamura, Y., Nakamura, K., Ikeda, S., Takahashi, H., Altaf-Ul-Amin, Md., Darusman, L. K., Saito, K., & Kanaya, S. (2012). KNApSAcK Family Databases: Integrated Metabolite–Plant Species Databases for Multifaceted Plant Research. Plant and Cell Physiology, 53(2), e1–e1. https://doi.org/10.1093/pcp/pcr165

Banerjee, P., Kemmler, E., Dunkel, M., & Preissner, R. (2024). ProTox 3.0: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Research, 52(W1), W513–W520. https://doi.org/10.1093/nar/gkae303

BIOVIA, D. S. (2016). Biovia Discovery Studio 2021 Client [Computer software]. https://discover.3ds.com/discovery-studio-visualizer-download?gclid=CjwKCAjwseSoBhBXEiwA9iZtxrm6rxhjDsp1Wlq-6que7TkYbdt3nzC_9j20wNd7MPxdt_Vh1Vns0xoC1IIQAvD_BwE

Cao, J., Zhang, M., Wang, B., Zhang, L., Zhou, F., & Fang, M. (2021). Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies. Frontiers in Oncology, 11, 658552. https://doi.org/10.3389/fonc.2021.658552

Chandrashekar, D. S., Bashel, B., Balasubramanya, S. A. H., Creighton, C. J., Ponce-Rodriguez, I., Chakravarthi, B. V. S. K., & Varambally, S. (2017). UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia, 19(8), 649–658. https://doi.org/10.1016/j.neo.2017.05.002

Chang, T. T., Thakar, D., & Weaver, V. M. (2017). Force-dependent breaching of the basement membrane. Matrix Biology, 57–58, 178–189. https://doi.org/10.1016/j.matbio.2016.12.005

Chavez, J. D., Keller, A., Zhou, B., Tian, R., & Bruce, J. E. (2019). Cellular Interactome Dynamics during Paclitaxel Treatment. Cell Reports, 29(8), 2371-2383.e5. https://doi.org/10.1016/j.celrep.2019.10.063

Cui, J., Chai, S., Liu, R., & Shen, G. (2024). Targeting PGK1: A New Frontier in Breast Cancer Therapy Under Hypoxic Conditions. Current Issues in Molecular Biology, 46(11), 12214–12229. https://doi.org/10.3390/cimb46110725

Faisal, M., & Hariaji, I. (2026). DNA-3-Methyladenine Glycosylase As Cancer Target Protein Of Gossypol Derivatives: A Computational Pharmacology Analysis. 9(1).

Faisal, M., Nurlaili, N., Graidist, P., & Tipmanee, V. (2022). Penambatan Molekul Senyawa Volatil Ekstrak Diklorometana Sambiloto Terhadap Jalur Pensinyal Epidermal Growth Factor Receptor: Penambatan Molekul Senyawa Volatil Ekstrak Diklorometana Sambiloto Terhadap Onkoprotein Human Epidermal Growth Factor Receptor. JURNAL BIOSENSE, 5(01), 67–80. https://doi.org/10.36526/biosense.v5i01.1948

Freihat, O., Sipos, D., & Kovacs, A. (2025). Global burden and projections of breast cancer incidence and mortality to 2050: A comprehensive analysis of GLOBOCAN data. Frontiers in Public Health, 13, 1622954. https://doi.org/10.3389/fpubh.2025.1622954

Fu, D., He, C., Wei, J., Zhang, Z., Luo, Y., Tan, H., & Ren, C. (2018). PGK1 is a Potential Survival Biomarker and Invasion Promoter by Regulating the HIF-1α–Mediated Epithelial-Mesenchymal Transition Process in Breast Cancer. Cellular Physiology and Biochemistry, 51(5), 2434–2444. https://doi.org/10.1159/000495900

He, Y., Luo, Y., Huang, L., Zhang, D., Hou, H., Liang, Y., Deng, S., Zhang, P., & Liang, S. (2024). Novel inhibitors targeting the PGK1 metabolic enzyme in glycolysis exhibit effective antitumor activity against kidney renal clear cell carcinoma in vitro and in vivo. European Journal of Medicinal Chemistry, 267, 116209. https://doi.org/10.1016/j.ejmech.2024.116209

He, Y., Luo, Y., Zhang, D., Wang, X., Zhang, P., Li, H., Ejaz, S., & Liang, S. (2019). PGK1-mediated cancer progression and drug resistance. American Journal of Cancer Research, 9(11).

Hu, X., Chen, W., Li, F., Ren, P., Wu, H., Zhang, C., & Gu, K. (2023). Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance. Frontiers in Oncology, 13, 1053125. https://doi.org/10.3389/fonc.2023.1053125

Liu, S., Zhang, X., Wang, W., Li, X., Sun, X., Zhao, Y., Wang, Q., Li, Y., Hu, F., & Ren, H. (2024). Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer. Molecular Cancer, 23(1), 261. https://doi.org/10.1186/s12943-024-02165-x

Meng, Y., Zhang, C., Feng, H., Lu, P., Wang, W., Pornprasert, S., He, T., & Lin, Y. (2025). Emerging trends and global collaboration in Paclitaxel resistance research for breast cancer: A comprehensive bibliometric study. Discover Oncology, 16(1), 1602. https://doi.org/10.1007/s12672-025-03420-3

Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30(16), 2785–2791. https://doi.org/10.1002/jcc.21256

Novriyanti, E., & Susilo, A. (2020). Conservation strategy for Taxus sumatrana, a species with limited geographical distribution yet limitless benefit and economic value. IOP Conference Series: Earth and Environmental Science, 533(1), 012006. https://doi.org/10.1088/1755-1315/533/1/012006

Oshiro, C., Marsh, S., McLeod, H., Carrillo, M. W., Klein, T., & Altman, R. (2009). Taxane pathway. Pharmacogenetics and Genomics, 19(12), 979–983. https://doi.org/10.1097/FPC.0b013e3283335277

Premchandani, T., Taksande, J., Tatode, A., Sheikh, S., Qutub, M., Hussain, U. M., Khan, R., & Umekar, M. (2025). Mitochondrial Dysfunction and Glycolytic Shift in the Tumor Microenvironment: Impact on Paclitaxel Efficacy in Cancer Therapy. Clinical Bioenergetics, 1(1), 5. https://doi.org/10.3390/clinbioenerg1010005

Qayum, M., Nisar, M., Rauf, A., Khan, I., Kaleem, W. A., Raza, M., Karim, N., Saleem, M. A., Bawazeer, S., Uysal, S., Zengin, G., Jahan, S., & Ramadan, M. F. (2020). In-vitro and in-silico anticancer potential of taxoids from Taxus wallichiana Zucc. Biologia Futura, 70(4), 295–300. https://doi.org/10.1556/019.70.2019.33

Shen, Y.-C., Wang, S.-S., Pan, Y.-L., Lo, K.-L., Chakraborty, R., Chien, C.-T., Kuo, Y.-H., & Lin, Y.-C. (2002). New Taxane Diterpenoids from the Leaves and Twigs of Taxus sumatrana. Journal of Natural Products, 65(12), 1848–1852. https://doi.org/10.1021/np0202273

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., & Norton, L. (2001). Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. New England Journal of Medicine, 344(11), 783–792. https://doi.org/10.1056/NEJM200103153441101

Sun, S., Liang, X., Zhang, X., Liu, T., Shi, Q., Song, Y., Jiang, Y., Wu, H., Jiang, Y., Lu, X., & Pang, D. (2015). Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer. British Journal of Cancer, 112(8), 1332–1339. https://doi.org/10.1038/bjc.2015.114

Tanaka, S., Matsunami, N., Morishima, H., Oda, N., Takashima, T., Noda, S., Kashiwagi, S., Tauchi, Y., Asano, Y., Kimura, K., Fujioka, H., Terasawa, R., Kawaguchi, K., Ikari, A., Morimoto, T., Michishita, S., Kobayashi, T., Sakane, J., Nitta, T., … Iwamoto, M. (2019). De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer. Cancer Chemotherapy and Pharmacology, 83(6), 1099–1104. https://doi.org/10.1007/s00280-019-03836-z

Wahyuni, F. S., Putri, D. E., Putra, Y. U., & Hamidi, D. (2024). Cytotoxic Activity Of Taxus Sumatrana (Miq.) De Laub. Bark, Leaves, And Shoots On Hela, T47d, And MCF-7/HER2 Cell Lines. International Journal of Applied Pharmaceutics, 93–98. https://doi.org/10.22159/ijap.2024.v16s1.23

Wang, P., Wang, Y.-Y., Xu, Y.-L., Zhang, C.-Y., Wang, K., & Wang, Q. (2023). Phosphoglycerate-kinase-1 Is a Potential Prognostic Biomarker in HNSCC and Correlates With Immune Cell Infiltration. Cancer Genomics - Proteomics, 20(6suppl), 723–734. https://doi.org/10.21873/cgp.20419

Wang, S., Jiang, B., Zhang, T., Liu, L., Wang, Y., Wang, Y., Chen, X., Lin, H., Zhou, L., Xia, Y., Chen, L., Yang, C., Xiong, Y., Ye, D., & Guan, K.-L. (2015). Insulin and mTOR Pathway Regulate HDAC3-Mediated Deacetylation and Activation of PGK1. PLOS Biology, 13(9), e1002243. https://doi.org/10.1371/journal.pbio.1002243

Weaver, B. A. (2014). How Taxol/paclitaxel kills cancer cells. Molecular Biology of the Cell, 25(18), 2677–2681. https://doi.org/10.1091/mbc.e14-04-0916

Yang, Z., & Han, Y. (2026). PGK1 is a prognostic molecule and silencing PGK1 inhibits the growth in breast cancer cells. Gene Reports, 42, 102396. https://doi.org/10.1016/j.genrep.2025.102396

Yu, H., Lan, F., Zhuang, Y., Li, Q., Zhang, L., Tian, H., Bu, X., Chen, R., Gao, Y., Wang, Z., & Zhang, L. (2025). Paclitaxel anti-cancer therapeutics: From discovery to clinical use. Chinese Journal of Natural Medicines, 23(7), 769–789. https://doi.org/10.1016/S1875-5364(25)60833-8

Zhu, L., Jiang, M., Wang, H., Sun, H., Zhu, J., Zhao, W., Fang, Q., Yu, J., Chen, P., Wu, S., Zheng, Z., & He, Y. (2021). A narrative review of tumor heterogeneity and challenges to tumor drug therapy. Annals of Translational Medicine, 9(16), 1351–1351. https://doi.org/10.21037/atm-21-1948